Breast Cancer Is Striking Later in Life—But Only for the Rich, 47-Year Study Finds

The average age at which American women are diagnosed with breast cancer has been creeping upward for nearly half a century, rising from 60.7 years in 1975 to 62.7 years by 2021. That two-year shift, documented across almost 700,000 cancer cases, might sound like a modest statistical footnote. It is anything but. The upward drift in diagnostic age—driven by longer life expectancy, changing reproductive patterns, evolving hormone use, and decades of widespread mammography screening—has shaped how screening guidelines are written and how clinicians think about who is at risk and when. But a sweeping new analysis of Surveillance, Epidemiology, and End Results (SEER) program data reveals that this well-documented trend is not a universal phenomenon. It is, to a striking degree, a privilege of wealth and geography.

The study, led by Soo Youn Bae of Seoul St. Mary’s Hospital at The Catholic University of Korea and colleagues, examined 696,960 women diagnosed with Stage I–III breast cancer between 1975 and 2021, drawing on the SEER 8 registries, the longest-running and most rigorously maintained cancer surveillance system in the United States. Rather than simply comparing average ages at the beginning and end of the period, the researchers modeled annual trajectories of diagnostic age using weighted ordinary least squares regression, estimating the rate of change—captured as a slope coefficient, β1—for each calendar year across every subgroup. The approach allowed them to detect not just whether diagnostic ages rose or fell, but how fast, at which cancer stage, and for whom.

The headline finding is a profound divergence along socioeconomic lines. Women living in the highest-income census tracts—the top quartile of neighborhood income—experienced significant, sustained increases in their age at diagnosis, consistent with the overall national trend toward later diagnosis. Women in the lowest-income quartile, by contrast, showed stagnant or even declining diagnostic ages. The pattern was particularly stark for Stage II disease: in the lowest-income group, the annual rate of change in diagnostic age was slightly negative, at β1 = −0.028 years per year, meaning that over the 46-year window, the average age at diagnosis for low-income women with Stage II breast cancer effectively moved backward while their wealthier counterparts aged into their diagnoses.

Geography told a parallel story. Women in rural communities, classified using the rural–urban continuum codes that rank counties from most metropolitan to most remote, similarly failed to participate in the national shift toward later diagnosis. Their diagnostic ages remained flat or drifted downward over the study period. The implication is uncomfortable: the demographic transition that has pushed breast cancer into later life for much of the population has simply bypassed the poorest and most geographically isolated women, whose tumors continue to be found at younger ages—and, given the established link between younger age at diagnosis for these groups and later-stage presentation, often at more dangerous points in the disease course.

The racial analysis added a second layer of complexity. Black women in the cohort showed the steepest annual increases in diagnostic age across all tumor stages, a trend that outpaced every other racial group. Yet despite this rapid upward trajectory, Black women remained younger at diagnosis than White women throughout the entire 46-year span. In other words, the fastest improvement in trajectory was not enough to close a persistent gap in the level. The finding captures a well-known paradox in breast cancer epidemiology: Black women are disproportionately diagnosed at younger ages and with more aggressive tumor subtypes, including higher rates of triple-negative and other hormone receptor–negative disease, while simultaneously facing barriers to timely screening and follow-up that delay detection within any given age band.

Why would diagnostic age rise for some groups and stall for others? The authors point to the intertwined machinery of screening access, reproductive and hormonal trends, and health care delivery. The national rise in diagnostic age partly reflects the aging of the population and the widespread adoption of screening mammography, which tends to detect cancers in older women earlier and more often. Mammography uptake, however, has never been evenly distributed. Studies spanning decades have documented lower screening rates among low-income women, rural residents, and some racial and ethnic minority groups, along with longer intervals between abnormal findings and diagnostic resolution. When screening is inconsistent, cancers are more likely to be detected symptomatically—and in groups with higher baseline risks of early-onset disease, that symptomatic detection skews young.

Hormone and reproductive factors plausibly deepen the divide. The rise and fall of menopausal hormone therapy—sharply curtailed after the Women’s Health Initiative reported increased breast cancer risk with combined estrogen plus progestin in 2002—altered incidence patterns, particularly among older, more affluent women who were most likely to use these therapies. Trends toward later childbearing, lower parity, and higher rates of obesity have reshaped risk profiles in ways that differ across socioeconomic strata. Higher-income women have, on balance, experienced risk-factor shifts associated with later-onset disease, while populations facing overlapping disadvantages have carried a heavier burden of early-onset, biologically aggressive tumors. The new trajectory data suggest these two forces have been quietly pulling the age of diagnosis apart for decades.

The technical rigor of the analysis lends weight to its conclusions. By stratifying simultaneously by stage, race, census tract income quartile, and rural–urban continuum code, and by applying weighted regression to annual mean diagnostic ages, the researchers could distinguish genuine temporal trends from artifacts of changing case mix. Stage-specific stratification matters because screening tends to shift the detected-stage distribution: rising diagnostic ages in Stage I disease can reflect early detection in older women, whereas declining or flat diagnostic ages in Stage II–III disease signal that some populations are not being caught by the early-detection net at all. The negative slope for low-income Stage II patients is precisely the signature one would expect if early-onset disease continues to dominate in a population that screening programs have failed to reach.

The policy implications are difficult to ignore. Current screening guidelines in the United States are built around age thresholds—typically recommending that average-risk women begin mammography in their 40s or 50s—implicitly assuming that breast cancer risk rises with age in a broadly uniform way. This study challenges that assumption by showing that the age structure of risk has diverged across social strata. A one-size-fits-all age-based policy, the authors argue, entrenches inequity: it calibrates optimally for high-income metropolitan women, whose diagnostic ages are rising, while under-serving low-income and rural women, whose disease continues to present earlier. Equitable, subgroup-specific screening strategies—whether through risk-adapted starting ages, enhanced outreach in underserved communities, mobile mammography in rural areas, or patient-navigation programs to shorten diagnostic delays—follow directly from the data.

The study also carries a broader lesson about how aggregate statistics can conceal inequality. Had the researchers stopped at the national average, the story would have been one of gradual progress: women, on the whole, are developing breast cancer later, and later diagnosis within a screened population generally correlates with better outcomes. Only by decomposing the trend did the deeper reality emerge—that the benefits of a half-century of progress in cancer detection and care have been distributed unevenly along lines of income, geography, and race. The two-year rise in mean diagnostic age is real, but it is an average of two very different worlds: one where women age into screenings and early detections, and another where cancer arrives early, often between screenings, and frequently at a stage that screening was supposed to prevent. Closing that diagnostic age gap, the authors conclude, is now one of the clearest quantitative targets for achieving equity in breast cancer control.

Subject of Research: Temporal trends in age at breast cancer diagnosis across socioeconomic, racial, and geographic subgroups in the United States from 1975 to 2021

Article Title: Temporal trajectories of age at breast cancer diagnosis by socioeconomic and geographic factors: a 1975–2021 SEER analysis

Article References: Bae, S. Y., Kim, C. W., Chin, J., Lee, J. A., Kim, D., Lee, Y. J., Yoon, C. I., & Park, W.-C. (2026). Temporal trajectories of age at breast cancer diagnosis by socioeconomic and geographic factors: a 1975–2021 SEER analysis. Cancer Causes & Control, 37(10), Article 160. https://doi.org/10.1007/s10552-026-02247-9

Image Credits: AI Generated

DOI: 10.1007/s10552-026-02247-9

Keywords: breast cancer, age at diagnosis, health disparities, socioeconomic factors, SEER, cancer screening, rural health, epidemiology, health equity, mammography, social determinants of health, cancer surveillance